#United States #Philadelphia #Integral Molecular #Cheryl Paes #commercial strategy

Integral Molecular Welcomes Cheryl Paes as VP of Commercial Strategy

Integral Molecular, a frontrunner in antibody discovery and characterization focusing on membrane proteins, has appointed Cheryl Paes as its Vice President of Commercial Strategy. This strategic hire is expected to stimulate the company’s growth in the biotech and pharmaceutical sectors.

With over 15 years of global expertise in biotechnology and life sciences, Paes has a proven track record in driving growth and innovation. In her prior roles with Meridian Life Science and Center for Breakthrough Medicines, she was instrumental in leading marketing and product management teams. Her focus on understanding customer needs and developing effective strategies helped various clients enhance their pipelines and improve their outcomes significantly. Furthermore, she has held senior commercial leadership positions at respected companies such as Clarivate Analytics and Zimmer Biomet.

Benjamin Doranz, CEO of Integral Molecular, expressed enthusiasm about Cheryl's appointment, stating, "We are excited to welcome Cheryl to Integral Molecular's leadership team. Her exceptional experience is vital for translating complex scientific platforms into effective solutions for our customers. With her guidance, we aim to deepen our partnerships, enhance access to our technologies, and prioritize customer needs in our operations."

Paes joins Integral Molecular at a crucial juncture as the company expands its range of antibody characterization technologies that are increasingly being adopted within the industry. One noteworthy innovation is the recently unveiled Paratope-PLUS™ service, leveraging the company's advanced CDR-Scanning technology to provide comprehensive antibody binding analysis. This service is designed to facilitate antibody engineering and offers critical data to bolster intellectual property rights.

In addition, Integral Molecular is progressing with its Membrane Proteome Array™ (MPA), a platform dedicated to specificity testing. This technology plays a pivotal role in ensuring the safety of antibodies, CAR-T cell therapies, and other biotherapeutics by identifying potential off-target interactions. The MPA is currently moving towards FDA qualification, aiming to establish it as the industry benchmark for therapeutic specificity testing.

Notably, Paes possesses a thorough understanding of the company's technologies, having previously contributed in scientific and business advisory capacities. On the horizon, she observes, "Integral Molecular is at an inflection point. The science is world-class, regulatory approval is within reach, and the biopharma industry is embracing the groundbreaking potential these technologies offer. Integral Molecular is ideally positioned to transform how partners tackle their most challenging issues, and I look forward to contributing to that journey."

To discover more about Integral Molecular’s antibody characterization platforms, visit integralmolecular.com.

About Integral Molecular

Integral Molecular is a leading innovator in developing technologies that advance therapeutic discovery against challenging protein targets. With a special focus on membrane proteins, viruses, and antibodies over its 25 years of operation, Integral Molecular's technologies are integral to the drug discovery processes of over 600 biotech and pharmaceutical companies. Their contributions are critical in identifying new therapies for a range of health concerns, including cancer, diabetes, autoimmune disorders, and viral threats like SARS-CoV-2, Ebola, Zika, and dengue viruses.

For updates, follow Integral Molecular on LinkedIn.